XML 39 R33.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Loss Before Income Tax - Additional Information (Details) € in Millions |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 12, 2018 USD ($) | Sep. 14, 2018 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2019 USD ($) | Oct. 31, 2019 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 21, 2019 EUR (€)
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Pre-launch inventory recognized |  |  |  |  |  | $ 28,000,000.0 |  | $ 28,900,000 |  |
Provision for obsolete stock |  |  |  |  |  | 300,000 |  | 500,000 |  |
Manufacturing Commercialization Expenses |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Pre-launch inventory recognized |  |  |  |  |  | 900,000 |  | $ 7,000,000.0 |  |
Grunenthal |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment received |  |  |  |  | $ 15,000,000.0 |  |  |  |  |
Milestone payment received |  |  |  | $ 2,500,000 |  |  |  |  |  |
Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines |  |  | 20.00% |  |  |  |  |  |  |
Non-refundable upfront payments receivable |  |  | $ 17,500,000 |  |  |  |  |  |  |
Cumulative milestone payments reachable amount |  |  | 1,000,000,000 |  |  |  |  |  |  |
Revenue recognized relation to patent license agreement |  |  |  |  |  | 0 | $ 0 |  |  |
Grunenthal | Clinical, Manufacturing, Regulatory and Reimbursement Approval | Top of Range |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payments receivable |  |  | $ 112,500,000 |  |  |  |  |  |  |
Tasly |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Deferred consideration up-front milestone receivable recognized | $ 20,000,000.0 |  |  |  |  | 20,000,000.0 |  |  |  |
Receipt on non refundable up-front payment upon reaching product regulatory milestone |  |  |  |  |  | 25,000,000.0 |  |  |  |
Revenue recognized from up-front payment as deferred consideration | $ 10,000,000.0 | $ 10,000,000.0 |  |  |  | 0 | 0 |  |  |
TiGenix NV |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Royalty income |  |  |  |  |  | 100,000 | 100,000 |  |  |
Milestone revenue in relation to patent license agreement |  |  |  |  |  | 0 | 1,200,000 |  |  |
Regulatory milestone payment receivable |  |  |  |  |  |  |  |  | $ 1,000,000.0 |
TiGenix NV | Top of Range |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Milestone revenue relating to non-refundable up-front payment | € |  |  |  |  |  |  |  |  |  | € 10.0
JCR Pharmaceuticals Co. Ltd |  |  |  |  |  |  |  |  |  |
Disclosure Of Loss Before Income Tax Line Item |  |  |  |  |  |  |  |  |  |
Royalties receivable under sales-based milestones |  |  |  |  |  | $ 1,400,000 | $ 2,300,000 |  |  |

X
- Definition The amount of income arising from royalties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueFromRoyalties
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount Entitled to be received on non refundable up-front payment upon reaching product regulatory milestone. + References No definition available. + Details
Name: | meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount Of Royalties Entitled To Be Received Upon Reaching Sales Based Milestones + References No definition available. + Details
Name: | meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cumulative milestone payments reachable amount. + References No definition available. + Details
Name: | meso_CumulativeMilestonePaymentsReachableAmount
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Deferred consideration milestone consideration recognized. + References No definition available. + Details
Name: | meso_DeferredConsiderationMilestoneConsiderationRecognized
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Disclosure Of Loss Before Income Tax Line Item. + References No definition available. + Details
Name: | meso_DisclosureOfLossBeforeIncomeTaxLineItem
Namespace Prefix: | meso_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | meso_MilestonePaymentReceived
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone revenue in relation to patent license agreement. + References No definition available. + Details
Name: | meso_MilestoneRevenueInRelationToPatentLicenseAgreement
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable up front payment received. + References No definition available. + Details
Name: | meso_NonRefundableUpFrontPaymentReceived
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable upfront payments receivable. + References No definition available. + Details
Name: | meso_NonRefundableUpfrontPaymentsReceivable
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines. + References No definition available. + Details
Name: | meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines
Namespace Prefix: | meso_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pre launch inventory recognized. + References No definition available. + Details
Name: | meso_PreLaunchInventoryRecognized
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Provision for obsolete stock. + References No definition available. + Details
Name: | meso_ProvisionForObsoleteStock
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory milestone payment receivable. + References No definition available. + Details
Name: | meso_RegulatoryMilestonePaymentReceivable
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue recognized for right of use license of IP. + References No definition available. + Details
Name: | meso_RevenueRecognizedForRightOfUseLicenseOfIP
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognized from up-front payment as deferred consideration. + References No definition available. + Details
Name: | meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties receivable under salesbased milestones. + References No definition available. + Details
Name: | meso_RoyaltiesReceivableUnderSalesBasedMilestones
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=meso_ManufacturingCommercializationExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RegulatoryEnvironmentsAxis=meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_TaslyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=meso_JCRPharmaceuticalsCoLTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |